Chengdu Galaxy Biomedical

Chengdu Galaxy Biomedical is a Chinese biotechnology company specializing in the development of innovative cell therapies and antibody-based drugs for oncology. As a core subsidiary of the Galaxy Biological group, the company focuses on advancing its proprietary CAR-T cell therapy platform to treat both hematological malignancies and solid tumors. Its lead candidate, Digal-19, is a CD19-targeted CAR-T therapy currently undergoing clinical evaluation for B-cell lymphoma and leukemia. Beyond cell therapy, the company is building a pipeline of monoclonal antibodies targeting immune checkpoints and tumor-associated antigens. Chengdu Galaxy Biomedical operates integrated research, development, and GMP-compliant manufacturing facilities in Chengdu to support its clinical programs.